Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|16|2999-3006

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.16, 2013-08, pp. : 2999-3006

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 328-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

p21‐activated kinase 1 predicts recurrence and survival in patients with non‐metastatic clear cell renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 5, 2015-05 ,pp. : 447-453

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents

By  

Oncology, Vol. 92, Iss. 5, 2017-02 ,pp. : 269-275

Karger

Access to resources Recommend Favorite

Editorial Comment to p21‐activated kinase 1 predicts recurrence and survival in patients with non‐metastatic clear cell renal cell carcinoma

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 5, 2015-05 ,pp. : 453-454

John Wiley & Sons Inc

Access to resources Recommend Favorite

Duration of Targeted Therapy for Metastatic Renal Cell Carcinoma: A Review of Current Practices

By  

Oncology, Vol. 82, Iss. 4, 2012-03 ,pp. : 189-196

Karger

Access to resources Recommend Favorite